{"id":"W3207786785","doi":"10.1016/j.jtho.2021.09.010","title":"First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Cilag; Janssen Pharmaceuticals; Sandoz; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Ipsen; Teijin Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; Clovis Oncology; AstraZeneca; Novocure; Merck KGaA; Taiho Pharmaceutical; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Johnson and Johnson; Teva Pharmaceutical Industries; Servier; Bayer; Gilead Sciences; Sanofi; University of Pennsylvania; Celgene; Novartis; GlaxoSmithKline; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Adverse effect; Confidence interval; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002125865,0.001881279,0.002937794,0.0003029538,0.0004466703,0.001642348,0.0011012,0.001783608,0.004431644],"category_scores_gemma":[0.00225639,0.0005669038,0.004603413,0.0002663788,0.000887772,0.001452433,0.0006070411,0.003746526,0.001054115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001696045,"about_ca_system_score_gemma":0.001224339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001651095,"about_ca_topic_score_gemma":0.003825165,"domain_scores_codex":[0.9992281,0.0003771345,0.00002978366,0.0001663197,0.00005722039,0.0001414786],"domain_scores_gemma":[0.998576,0.0004148233,0.0003910343,0.0001545861,0.00007808889,0.0003853873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9646459,0.003584852,0.002537137,0.0008092875,0.003828227,0.00004521074,0.00006711155,0.001343523,0.002276674,0.0001395309,0.003055616,0.01766708],"study_design_scores_gemma":[0.9256,0.05585193,0.01145105,0.00009416403,0.003547556,0.00008776793,0.00005263789,0.001017342,0.0007377953,0.0003404676,0.001174107,0.00004516988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860366,0.005926041,0.0004402947,0.0008745547,0.0004022288,0.000983548,0.003363901,0.0001325005,0.001840246],"genre_scores_gemma":[0.9834039,0.002632078,0.0009230006,0.001472968,0.0004744193,0.001414792,0.006339463,0.00005590444,0.003283525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004431644,"threshold_uncertainty_score":0.01482528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06623119738577873,"score_gpt":0.4494461952160643,"score_spread":0.3832149978302856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}